Praised Be Placebo, May Its Glory Shine

Sartorius, Norman
February 2006
Croatian Medical Journal;2006, Vol. 47 Issue 1, p189
Academic Journal
Presents information on placebo. Explanation on the term placebo in clinical trials and in clinical practice; Reason comparing a new drug to another of known efficacy usually requires larger groups and patients and controls; Reflections on healthcare.


Related Articles

  • How can research ethics committees protect patients better? Garattini, Silvio; Bertele, Vittorio; Bassi, Luca Li // BMJ: British Medical Journal (International Edition);5/31/2003, Vol. 326 Issue 7400, p1199 

    The potentially enormous profits mean that to comply with their duty and act in the interest of patients and public health, research ethics committees have to carefully assess clinical protocols with the necessary scientific knowledge and evaluate the true objectives of new studies and the...

  • Composite End points: Proceed with Caution. Kleist, Peter // Applied Clinical Trials;May2006, Vol. 15 Issue 5, p50 

    The article discusses the use of valid primary endpoint for a randomized controlled trial (RCT) designed to demonstrate efficacy of a new pharmaceutical drug in clinical trials. A composite endpoint consists of multiple single endpoints that are combined in order to confront an investigational...

  • O2–035SAFETY AND EFFICACY OF REGORAFENIB IN JAPANESE PATIENTS WITH METASTATIC COLORECTAL CANCER: A SUBGROUP ANALYSIS OF THE PHASE III CORRECT TRIAL. Yamada, Y.; Yoshino, T.; Komatsu, Y.; Yamazaki, K.; Tsuji, A.; Ura, T.; Grothey, A.; Van Cutsem, E.; Wagner, A.; Ohtsu, A. // Annals of Oncology;Nov2013 Supplement 9, Vol. 24, pix49 

    No abstract available.

  • HEART FAILURE. Gorog, Diana; Kapur, Akhil; Khan, Masood; Lindsay, Alistair; Sharp, Andrew // Heart;Mar2006, Vol. 92 Issue 3, p431 

    The article focuses on CHARM, a double blind, randomized, controlled clinical trial, comparing the effects of the angiotensin receptor blocker candesartan with placebo in patients with chronic heart failure. The findings suggests that adherence is a marker for adherence to effective treatments...

  • Clinical trial: active control vs placebo--What is ethical? Splawinski, Jacek; Kuzniar, Jerzy // Science & Engineering Ethics;Jan2004, Vol. 10 Issue 1, p73 

    The quest for effective medicines is very old. In modern times two important tools have been developed to evaluate efficacy of' drugs: superiority and non-inferiority types of clinical trials. The former tests the null hypothesis of μ (the difference between a tested drug and comparator)...

  • Prucalopride for Severe Constipation.  // Clinical Cardiology Alert;Aug2008 Primary Care Supplement, Vol. 13 Issue 8, p16 

    The article discusses research on the use of prucalopride (PRU) against chronic constipation. It references a study by M. Camilleri et al published in a 2008 issue of the "New England Journal of Medicine." According to a double-blind trial of the drug, thirty one percent of patients taking PRU...

  • Evaluation of sexual activity in patients treated with tadalafil: a randomized prospective placebo-controlled trial. De Rose, A F; Gallo, F; Carmignani, G // International Journal of Impotence Research;Feb2005, Vol. 17 Issue 1, p76 

    The chronological distribution of sexual intercourses in a group of patients treated with tadalafil versus placebo for 3 months was evaluated. In total, 120 patients with ED were randomized in two groups and treated, respectively, with one pill of tadalafil 20?mg or placebo on Tuesday and on...

  • Memantine plus donepezil improves physical and mental health in people with Alzheimer's disease. Tariot, P. N.; Farlow, M. R.; Grossberg, G. T. // Evidence Based Mental Health;Aug2004, Vol. 7 Issue 3, p76 

    The article investigates whether memantine, in combination with donepezil, improve physical and mental health in people with Alzheimer's disease. A randomized controlled trial was conducted for this purpose. 404 people receiving donepezil treatment for moderate to severe Alzheimer's disease were...

  • Placebo Response in Antipsychotic Clinical Trials. Rutherford, Bret R.; Pott, Emily; Tandler, Jane M.; Wall, Melanie M.; Roose, Steven P.; Lieberman, Jeffrey A. // JAMA Psychiatry;Dec2014, Vol. 71 Issue 12, p1409 

    IMPORTANCE: Because increasing placebo response rates decrease drug-placebo differences and increase the number of failed trials, it is imperative to determine what is causing this trend. OBJECTIVES: To investigate the relationship between antipsychotic medication and placebo response by...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics